Anti-CDCP1 antibody drug conjugate - MMAE - Chiome Bioscience
Alternative Names: Anti-CDCP1 antibody drug conjugate - monomethyl auristatin E- Chiome BioscienceLatest Information Update: 22 Jun 2023
At a glance
- Originator Chiome Bioscience
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Jun 2023 Anti-CDCP1 antibodies - MMAE - Chiome Bioscience is available for licensing as of 16 Jun 2023. https://www.chiome.co.jp/pipeline/
- 16 Jun 2023 Chiome Bioscience has filed patent application for method for producing specific antibody in Japan, US, Europe and China (Chiome Bioscience website, June 2023)
- 16 Jun 2023 Chiome Bioscience has filed patent application for Cells that produce human antibodies in Japan, US, Europe and China (Chiome Bioscience website, June 2023)